Silent Epidemic: Metabolic Liver Disease Set to Impact 1.8 Billion by 2050
A concerning new study paints a stark picture of the future of liver health. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is rapidly becoming a global health crisis, projected to affect a staggering 1.8 billion people worldwide by 2050. This represents a 42% increase from the 1.3 billion already living with the condition in 2023.
The Scale of the Problem: A Global Surge
The research, published in The Lancet Gastroenterology & Hepatology and conducted by the Institute for Health Metrics and Evaluation, reveals a dramatic rise in MASLD cases over the past three decades. In 1990, approximately 500 million people were affected. Today, that number has more than doubled, with roughly one in six people – 16% of the global population – now living with MASLD.
While the disease is spreading worldwide, certain regions are experiencing disproportionately higher rates. North Africa and the Middle East are particularly affected. Although, increases are being observed across the globe, including a 33% rise in the UK between 1990 and 2023 – the largest increase in western Europe. Australia and the United States have as well seen significant increases, with prevalence rates climbing by 30% and 22% respectively.
Who is Most at Risk?
MASLD is more prevalent in men than in women. The highest rates are found in older adults, specifically those aged between 80, and 84. Interestingly, the largest number of cases are occurring in younger adults – around 35 to 39 in men and 55 to 59 in women – suggesting a shift in the age demographics affected by the disease.
Did you know? MASLD often presents no noticeable symptoms, meaning many individuals are unaware they have the condition until it’s discovered during testing for other health issues.
The Driving Forces Behind the Increase
The study identifies high blood sugar as the leading driver of MASLD-related health problems globally. High BMI and smoking are also significant contributing factors, highlighting the strong links between MASLD and type 2 diabetes and obesity. Global population growth combined with lifestyle changes are projected to fuel further increases in cases.
A Silver Lining? Stabilizing Health Impact
Despite the dramatic increase in the number of cases, the overall impact on health – measured in years lost due to illness or death – has remained stable. This suggests that advances in treatment and care are helping people live longer and healthier lives, and that many new cases are being identified in the early stages of the disease.
However, experts caution that the growing number of cases still poses a significant risk, as many individuals may eventually develop serious complications such as liver cirrhosis or cancer.
What is MASLD and What Can Be Done?
MASLD is often linked to being overweight and is frequently treatable with lifestyle changes. Symptoms, when they do appear, can include fatigue, general malaise, and discomfort or pain in the upper right abdomen.
Pro Tip: Maintaining a healthy weight, managing blood sugar levels, and avoiding smoking are crucial steps in preventing and managing MASLD.
Frequently Asked Questions (FAQ)
What is the difference between MASLD and NAFLD? MASLD is the updated term for non-alcoholic fatty liver disease (NAFLD). The change reflects a better understanding of the metabolic factors driving the condition.
Is MASLD serious? Yes, if left untreated, MASLD can lead to serious complications like cirrhosis and liver cancer.
How is MASLD diagnosed? MASLD is typically diagnosed through blood tests and imaging scans, often discovered during routine check-ups or when investigating other health concerns.
Can diet changes aid? Yes, lifestyle changes, particularly dietary modifications and increased physical activity, are often the first line of treatment for MASLD.
Want to learn more about liver health and preventative measures? Explore our other articles on metabolic health.
